APA (7th ed.) Citation

E, G., TT, H., JR, N., G, Z., A, M., D, N., . . . JM, L. (2024). The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: A phase 2 trial. Nature communications, 15(1), 2805. https://doi.org/10.1038/s41467-024-47215-6

Chicago Style (17th ed.) Citation

E, Giudice, et al. "The CHK1 Inhibitor Prexasertib in BRCA Wild-type Platinum-resistant Recurrent High-grade Serous Ovarian Carcinoma: A Phase 2 Trial." Nature Communications 15, no. 1 (2024): 2805. https://doi.org/10.1038/s41467-024-47215-6.

MLA (9th ed.) Citation

E, Giudice, et al. "The CHK1 Inhibitor Prexasertib in BRCA Wild-type Platinum-resistant Recurrent High-grade Serous Ovarian Carcinoma: A Phase 2 Trial." Nature Communications, vol. 15, no. 1, 2024, p. 2805, https://doi.org/10.1038/s41467-024-47215-6.